The atypical antipsychotic drugs (AAPDs) have markedly enhanced the treatment of schizophrenias but their use has been hindered by the major weight gain elicited by some AAPDs. We found that orexigenic AAPDs potently and selectively activate hypothalamic AMP kinase (AMPK), an action abolished in mice with deletion of histamine Hl receptors. These findings afford a means of developing better therapeutic agents and provide insight into the hypothalamic regulation of food intake.
METHODS FOR PREDICTING PSYCHOTROPIC DRUGS WHICH ELICIT WEIGHT GAIN